BALTIMORE, July 13 /PRNewswire/ -- BioFortis announced today that the National Cancer Institute (NCI) at the National Institutes of Health has selected its software, Labmatrix(TM), for use within its Center for Cancer Research (CCR). The CCR, NCI’s intramural research program, is comprised of multiple labs, branches and core facilities supporting both clinical and basic sciences, with a focus on translational cancer research.
Labmatrix, a web-based, enterprise translational research information management software product, is being used to support human subjects research by seamlessly integrating clinical data with genomic, proteomic and laboratory experimental data, as well as maintain annotated tissue banks. CCR’s decision to adopt the Labmatrix technology came after extensive user evaluation within the Neuro Oncology Branch. An analysis was also conducted of requirements to interface with existing CCR infrastructure utilizing caBIG interoperability standards. Existing infrastructure included clinical trials data management, patient registry and reporting systems.
Labmatrix’ ability to track human biological specimens, IRB (Institutional Review Board) consents, sample usage and downstream analytical results, is especially important in today’s regulatory environment, which demands responsibility and accountability from researchers and research administrators to document and maintain audit trails of all use of human specimens for research.
“NCI’s decision to implement Labmatrix, after extensive trials and very positive user feedback, is clear demonstration of the value of our technology for clinical and translational research. The relationship with NCI is a key element of our strategy to support collaborative biomedical research for a much wider user base in the government, academic and biopharmaceutical industry segments,” said Dr. Jian Wang, the company’s President and CEO.
Labmatrix was developed in close collaboration with scientists at the NIH and other leading research institutions. Utilizing a disease-neutral design, Labmatrix supports current users at the forefront of biomedical research that conduct a wide range of studies spanning the range of human diseases, including those in immunology, oncology, neurology, ophthalmology, metabolism and other hereditary and sporadic disorders.
About BioFortis
BioFortis, located at the Emerging Technology Center in Baltimore, Maryland, is a privately-held company focused on providing biomedical research software and services to the life sciences sector, including clinical and basic research laboratories within academic medical centers, government labs, non-profit institutes, research consortia and the biopharmaceutical industry. BioFortis’ flagship product Labmatrix(TM) enables transparent data management, integration, collaboration and compliance to privacy regulations. Labmatrix encompasses data management and cross-cutting query capabilities across patient information, biological sample data, workflow and storage, disease phenotypes, genotypes, clinical and molecular data, study and IRB protocol management.
BioFortis
CONTACT: Jian Wang, Ph.D. of BioFortis, Inc., +1-410-327-4082 ext.1167,jwang@biofortis.com
Web site: http://www.biofortis.com/
